Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinshu capsule versus Xinkeshu capsule for stable angina pectoris with qi and blood stasis syndrome
ChiCTR-TRC-14004529Phase 4Completed
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of daclizumab in coronary arteriosclerosis and angina pectoris (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoints: Angina symptom score, Exercise treadmill total exercise duration and 6 more. Started Apr 2014; status: completed.
02
Drugs
daclizumab
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on ChiCTR-TRC-14004529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004529.